Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01314118 · ClinicalTrials.gov registry record · Phase 2

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

A Phase 2 study of Prostate Cancer and Prostatic Neoplasm, sponsored by Janssen Biotech.

Completed
Registry status
Phase 2
Development phase
131
Enrollment target
20
Study locations

NCT01314118 is a Phase 2 study of Prostate Cancer and Prostatic Neoplasm that has completed, run by Janssen Biotech. The registered enrollment target is 131 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01314118, a Phase 2 study of Prostate Cancer and Prostatic Neoplasm, has completed, sponsored by Janssen Biotech.

COMPLETED
Registry status
Phase 2
Development phase
131 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last.

Conditions Studied

Prostate Cancer Prostatic Neoplasm

Interventions

  • DRUG abiraterone acetate in combination with prednisone

Study Locations (20)

Illinois

  • - Evanston
  • - Galesburg
  • - Glenview
  • - Melrose Park

California

  • - Los Angeles
  • - San Diego
  • - San Francisco

Alabama

  • - Homewood
  • - Huntsville

Colorado

  • - Aurora
  • - Denver

Florida

  • - Aventura
  • - Orange City

Indiana

  • - Fort Wayne
  • - Jeffersonville

Maryland

  • - Baltimore
  • - Rockville

Arizona

  • - Tucson

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2011-05-04
Est. Completion 2024-12-02
Phase Phase 2

Sponsor

Janssen Biotech

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01314118

The ClinicalTrials.gov registry entry for NCT01314118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Janssen Biotech, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which abiraterone acetate in combination with prednisone is the first listed.

NCT01314118 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Illinois, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT01314118 about?

NCT01314118 is a clinical study titled "IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen". The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information a...

What is the current status of trial NCT01314118?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2011-05-04. Estimated completion is 2024-12-02.

What conditions does trial NCT01314118 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasm.

What interventions are being tested in trial NCT01314118?

The interventions under investigation include: abiraterone acetate in combination with prednisone (DRUG).

Who is sponsoring clinical trial NCT01314118?

This trial is sponsored by Janssen Biotech, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01314118 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Prostatic Neoplasm

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.